MedPath

PRIYANKA SHARMA

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

12

Active:1
Completed:2

Trial Phases

3 Phases

Phase 1:2
Phase 2:2
Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (37.5%)
Phase 1
2 (25.0%)
Phase 2
2 (25.0%)
phase_2_3
1 (12.5%)

HER2-positive Breast Cancer Registry

Recruiting
Conditions
HER2 + Breast Cancer
First Posted Date
2024-09-19
Last Posted Date
2024-10-03
Lead Sponsor
Priyanka Sharma
Target Recruit Count
1000
Registration Number
NCT06603597
Locations
🇺🇸

KUCC - Indian Creek, Overland Park, Kansas, United States

🇺🇸

KCCC Overland Park, Overland Park, Kansas, United States

🇺🇸

KUCC - North, Kansas City, Missouri, United States

and more 2 locations

Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Phase 2
Completed
Conditions
Triple-negative Breast Cancer
Interventions
First Posted Date
2015-04-09
Last Posted Date
2021-05-10
Lead Sponsor
Priyanka Sharma
Target Recruit Count
101
Registration Number
NCT02413320
Locations
🇺🇸

University of Kansas Cancer Center - CRC, Fairway, Kansas, United States

🇺🇸

Hays Medical Center, Hays, Kansas, United States

🇺🇸

University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States

and more 6 locations

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1
Active, not recruiting
Conditions
Breast Cancer
Triple-Negative Breast Cancer
Interventions
First Posted Date
2015-03-19
Last Posted Date
2023-04-27
Lead Sponsor
Priyanka Sharma
Target Recruit Count
51
Registration Number
NCT02393794
Locations
🇺🇸

University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States

🇺🇸

University of Kansas Cancer Center - West, Kansas City, Kansas, United States

🇺🇸

University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States

and more 4 locations

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
Drug: BYL-719 (alpelisib)
First Posted Date
2015-03-04
Last Posted Date
2022-06-07
Lead Sponsor
Priyanka Sharma
Target Recruit Count
43
Registration Number
NCT02379247
Locations
🇺🇸

University of Kansas Cancer Center, Kansas City, Kansas, United States

🇺🇸

University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States

🇺🇸

University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.